title: Preventive effect of ipragliflozin on nocturnal hypoglycemia in patients with type 2 diabetes treated with basal-bolus insulin therapy: An open-label, single-center, parallel, randomized control study.
abstract: The efficacy of the administration of sodium-glucose co-transporter 2 inhibitor or the co-administration of sodium-glucose co-transporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor to insulin therapy is not well known. A total of 58 patients with type 2 diabetes, admitted for glycemic control, were randomized to basal-bolus insulin therapy (BBT) alone or BBT plus 50 mg ipragliflozin and/or 20 mg teneligliptin. Insulin doses were adjusted to maintain normal blood glucose levels. Plasma glucose profiles were estimated by continuous glucose monitoring before discharge. Required insulin doses were not significantly different among the treatment groups. The frequency of nocturnal hypoglycemia was significantly lower in the groups treated with ipragliflozin (6.5 ± 10.6%) and ipragliflozin plus teneligliptin (6.9 ± 14.3%) than in the group treated with BBT alone (42 ± 43.6%). The administration of sodium-glucose co-transporter 2 inhibitor with or without dipeptidyl peptidase-4 inhibitor prevented nocturnal hypoglycemia in type 2 diabetes patients with BBT.
authors.affiliation: Division of Endocrinology, Department of Medicine, Chiba-Hokusoh Hospital, Nippon Medical School, Chiba, Japan.|Department of Endocrinology, Diabetes and Metabolism, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
authors.forename: Fumitaka
authors.identifier: http://orcid.org/0000-0002-7588-6761
authors.initials: F
authors.lastname: Okajima
authors.affiliation: Division of Endocrinology, Department of Medicine, Chiba-Hokusoh Hospital, Nippon Medical School, Chiba, Japan.|Department of Endocrinology, Diabetes and Metabolism, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
authors.forename: Tomoko
authors.initials: T
authors.lastname: Nagamine
authors.affiliation: Division of Endocrinology, Department of Medicine, Chiba-Hokusoh Hospital, Nippon Medical School, Chiba, Japan.|Department of Endocrinology, Diabetes and Metabolism, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
authors.forename: Yuko
authors.initials: Y
authors.lastname: Nakamura
authors.affiliation: Division of Endocrinology, Department of Medicine, Chiba-Hokusoh Hospital, Nippon Medical School, Chiba, Japan.|Department of Endocrinology, Diabetes and Metabolism, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
authors.forename: Naomi
authors.initials: N
authors.lastname: Hattori
authors.affiliation: Department of Endocrinology, Diabetes and Metabolism, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Sugihara
authors.affiliation: Division of Endocrinology, Department of Medicine, Chiba-Hokusoh Hospital, Nippon Medical School, Chiba, Japan.|Department of Endocrinology, Diabetes and Metabolism, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
authors.forename: Naoya
authors.initials: N
authors.lastname: Emoto
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D005960:Glucosides / Q000627:therapeutic use*; D006801:Humans; D007003:Hypoglycemia / Q000150:complications / Q000517:prevention & control*; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use*; D008875:Middle Aged; D011720:Pyrazoles / Q000627:therapeutic use; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D053778:Thiazolidines / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: C579035:3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine; D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D005960:Glucosides; D007004:Hypoglycemic Agents; D007328:Insulin; D011720:Pyrazoles; C089180:SLC5A2 protein, human; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D053778:Thiazolidines; D013876:Thiophenes; C572941:ipragliflozin
keywords: Basal-bolus insulin therapy; Nocturnal hypoglycemia; Sodium-glucose co-transporter 2 inhibitor